HOME>News Release

News Release

  • Mitsubishi Tanabe Pharma
  • Former TANABE SEIYAKU
  • Former Mitsubishi Pharma
  • RSS
  • About RSS

2018

July 19
Mitsubishi Tanabe Pharma Receives The 43rd (FY2018) Inoue Harushige Prize ― A challenge for the new drug against amyotrophic lateral sclerosis (ALS), research and development of edaravone―PDFNEW
July 2
Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” - Toward the Innovative Drug Discovery for refractory Neurological Diseases -PDF
July 2
Open Call for Applicants for Researcher-Initiated Clinical Research Funds - We Ensure Transparency and Support Investigator-Initiated Research Based on Japan's Clinical Research Act -PDF
June 28
Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K.K. update co-promotion framework for STELARA, an anti-IL-12/23p40 monoclonal antibody Distribution will be transferred to Mitsubishi Tanabe Pharma, while the two companies will continue co-promotion of STELARA to treat adults with Crohn’s disease in JapanPDF
June 14
TFDA approves Clenafin/Jublia for the treatment of Onychomycosis in TaiwanPDF
May 30
Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development―Start of collaborative/competitive drug discovery research by three academic institutions and three pharmaceutical companiesPDF
May 28
For the ALS patients in the world,we hope to deliver Japan-originated ALS treatment―EMA accepts our filing for Edaravone to treat ALSPDF
May 18
Canagliflozin (Antidiabetic agent) wins The Technology Award Grand Prize fromthe Japan Chemical Industry Association (JCIA)PDF
May 9
Announcement of Financial Results for FY2017
⇒R&D Pipeline "State of New Product Development"
April 10
Update of Previous Disclosure ― Announcement of Filing a Request for Arbitration on the Licensing Agreement with Kolon Life SciencePDF
April 10
To ALS patients in the world, we hope to deliver Japan-originated ALS treatment―Health Canada accepts our filing for Edaravone to treat ALS and we established commercializing company in CanadaPDF
March 26
Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug DevelopmentPDF
March 6
Name Change of our Singapore SubsidiaryPDF
March 1
Mitsubishi Tanabe Pharma Group started marketing CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitus in TaiwanPDF
February 28
Valixa Tablet 450mg ―Public knowledge-based application for an additional pediatric indication for the prevention of CMV disease in organ transplant patients as well as application for an additional dosage form of dry syrupPDF
February 5
Announcement of FY2017 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
January 23
Swissmedic accepts our filing for Edaravone to treat ALS ― To ALS patients in the world, we hope to deliver Japan-originated ALS treatmentPDF
January 16
Approval in China Received for Additional Novastan Indication for Acute Cerebral Infarction ― Reinforcing Our Pharmaceutical Development and Sales in China, the World's Second Largest Pharmaceutical MarketPDF
January 11
Launch of "KREMEZIN Tablets 500mg" (Additional Formulation), Drug for Chronic Renal Failure ― For Improving Patients' Usage Experience and Medication Adherence ―PDF

2017

December 20
Update of Previous Disclosure ― License Agreement with Kolon Life Science on InvossaPDF
December 13
Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALSPDF
November 22
Launch of Rupafin tablets in Japan ―Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)PDF
November 8
Distribution Agreement for Clenafin/Jublia in TaiwanPDF
November 1
Announcement of FY2017 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
November 1
Notice Regarding Mitsubishi Tanabe Pharma’s Acquisition of Stelic Institute & Co., Inc. Securing Nucleic Acid Pharmaceuticals of Inflammatory bowel disease for Future Launch in the U.S.PDF
November 1
Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal AnemiaPDF
October 24
Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2018PDF
October 18
Completion of Acquisition of NeuroDerm (100% Ownership)PDF
October 11
Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library -Three Japanese pharmaceutical companies collaborate in facilitating drug discovery in Japan through open innovation sharing of compounds developed by the companies-PDF
October 2
Completion of Transfer of Shares of Generic Drugs Subsidiary (Update of Previous Disclosure)PDF
September 29
Organizational Change and Personnel ChangePDF
September 27
Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)PDF
September 27
Notice of the Start of Phase 3 Clinical Study of VLP Seasonal Influenza VaccinePDF
September 13
Approval of Mitsubishi Tanabe Pharma’s Acquisition of NeuroDerm at NeuroDerm’s General Meeting of ShareholdersPDF
September 7
Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Launch of CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent-Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets-PDF
September 4
Start of Operations of Vaccine Manufacturing Joint Venture: BIKEN Co., Ltd.PDF
August 17
Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in OsteoarthritisPDF
July 31
Announcement of FY2017 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
July 27
Notice regarding the initiation of a phase 2/3 clinical trial in Japan for tardive dyskinesia patients for VMAT2 inhibitor MT-5199PDF
July 24
Mitsubishi Tanabe Pharma to Acquire NeuroDerm Ltd.PDF
July 3
Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug ―Application approved in Japan for CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent -Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets-PDF
June 30
Conclusion of Agreement on Absorption-Type Company Split of Generic Drugs and Part of the Long-Listed Products BusinessPDF
June 20
Fingolimod Hydrochloride wins Patent Infringement Lawsuit in the U.S. District CourtPDF
June 1
Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund’s second phase ―Targeting treatments for infectious diseases that burden the developing world―PDF
May 18
Approval for partial change in administration / dosage for Crohn’s disease for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibodyPDF
May 16
Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALSPDF
May 10
Differences Between Non-Consolidated Actual Results for FY2015 and FY2016PDF
May 10
Announcement of Financial Results for FY2016
⇒R&D Pipeline "State of New Product Development"
May 10
Notice of Dividend of Retained EarningsPDF
May 10
Notice Regarding Revision of Business Structure for Recombinant Human Serum Albumin PreparationPDF
May 9
Establishment of Vaccine Manufacturing Joint Venture: BIKEN CO.,Ltd.PDF
May 8
New Japan-originated ALS treatment option available to patients in the U.S. ―U.S. FDA approves RADICAVA (edaravone) for the treatment of ALSPDF
April 26
Introduction of Performance-Linked Stock Compensation Plan for Board DirectorsPDF
April 24
Mitsubishi Tanabe Pharma Group receives import and marketing permission in Taiwan for CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitusPDF
April 17
Notice regarding overseas subsidiary MT Pharma (Thailand) Strengthening business development in the ASEAN regionPDF
March 30
Notice regarding approval of indication of ulcerative colitis and additional formulation for SIMPONI subcutaneous injection 50mg syringe (generic name: golimumab), a human monoclonal antibody specific for human TNF αPDF
March 29
Mitsubishi Tanabe Pharma and Daiichi Sankyo to Expand Strategic Alliance in the Diabetes Field The companies enter into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, following co-operation for TENELIA Tablets, a selective DPP-4 inhibitor, and CANAGLU Tablets, an SGLT2 inhibitorPDF
March 28
Split off and transfer of Generic Drugs and Part of Long-Listed Products Business and Change of SubsidiaryPDF
February 6
Announcement of FY2016 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
February 3
Mitsubishi Tanabe Pharma Corporation Strategically Strengthens Its Foundation in the Field of Inflammatory Bowel Disease Mitsubishi Tanabe Pharma signs co-promotion agreement with Janssen Pharmaceutical K.K. for STELARA for an indication of Crohn’s diseasePDF
January 27
Biogen and Mitsubishi Tanabe Pharma Terminate the License Agreement on MT-1303PDF

News Release

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide